Ipamorelin
Selective ghrelin-receptor agonist that releases GH without large cortisol/prolactin effects; failed in phase 2 for ileus.
Not FDA-approved. Not approved. WADA-prohibited. FDA Category 2 bulk listing. This page describes research and public discussion; it is not a recommendation to use.
Overview
Ipamorelin is a pentapeptide growth-hormone secretagogue. It was tested by Helsinn for post-operative ileus but did not outperform placebo in phase 2. Selectivity for GH release has been shown in animals and early human pharmacology.
Mechanism of action
Agonist at the GHS-R1a (ghrelin) receptor, triggering pituitary GH pulses.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Phase 2 post-operative ileus B Human clinical data No significant benefit vs placebo. | 0.03 mg/kg | Twice daily | Up to 7 days | IV |
Online protocols D Anecdotal / community | 100–300 mcg | 1–3× daily | 8–12 weeks | Subcutaneous |
Clinical trials & studies
- Animal1998Ipamorelin, the first selective GH secretagogue (Eur J Endocrinol)
Swine pharmacology demonstrating selectivity.
- Phase 22014Ipamorelin for postoperative ileus — phase 2 (Int J Colorectal Dis)
No significant difference vs placebo.
Safety
Side effects
- Hunger, flushing, headache
- Water retention
- Glucose elevation (GH class)
Contraindications
- Active cancer
- Pregnancy
Interactions
- Other GH secretagogues
- Diabetes medication
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Not approved. WADA-prohibited. FDA Category 2 bulk listing.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.